Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

DynamHet

Financiado

Deciphering the dynamic-plasticity and heterogeneity of cancer-associated fibrob...

Cancer-associated fibroblasts (CAFs) are one of the most abundant and versatile cell types in the tumour microenvironment (TME), where they crosstalk with stromal cells and actively participate in tumour development. Because of th... ver más

31/08/2028

FUNDACIO CLINIC PE...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5 | 650K€

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-05-05

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-STG: ERC STARTING GRANTS

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

FUNDACIO CLINIC PER A LA REC...

1.78M€ | Lider

Proyectos interesantes

RTI2018-096778-A-I00 IDENTIFICACION Y CARACTERIZACION DE ESTRATEGIAS PARA MODULAR... 169K€ Cerrado

CNS2023-145267 Cáncer 200K€ Cerrado

PID2021-122292NA-I00 INTERACCION FIBROBLASTO-MACROFAGO EN CANCER 248K€ Cerrado

PID2019-104698RB-I00 DISECCIONADO LA ACCION DEL MICROAMBIENTE SOBRE LA PROGRESION... 266K€ Cerrado

PID2021-123199OB-I00 DETERMINANTES MOLECULARES IMPLICADOS EN LA UNION/CAPTACION D... 202K€ Cerrado

PID2021-128107OB-I00 ESTRATEGIAS PARA SILENCIAR LA COMUNICACION ENTRE LOS FIBROBL... 327K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 63 meses Fecha Inicio: 2023-05-05
Fecha Fin: 2028-08-31

Líder del proyecto

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA

TRL 4-5 | 650K€

Presupuesto del proyecto 2M€

Descripción del proyecto Cancer-associated fibroblasts (CAFs) are one of the most abundant and versatile cell types in the tumour microenvironment (TME), where they crosstalk with stromal cells and actively participate in tumour development. Because of their assumed pro-tumourigenic functions, CAFs have long been considered an attractive therapeutic target. However, recent evidence indicates that multiple CAF subpopulations showing inflammatory, myofibroblastic, vascular, antigen-presenting, and immunosuppressive phenotypes co-exist within the same tumour, – with some promoting and other restricting tumour growth; thus, making their targeting challenging. How CAFs change dynamically as cancers evolve, and how this may affect the overall tumour heterogeneity, remains unaddressed. Therefore, the main goal of DynamHet is to elucidate the origin and evolution of CAF heterogeneity and to decipher the mediators and mechanisms that regulate CAF plasticity as the tumour advances. This is crucial for the development of effective therapies aimed at reprogramming CAFs towards therapeutically favourable phenotypes and will constitute a great breakthrough in the field of oncology. Hence, DynamHet aims to 1) decipher the origin of CAF heterogeneity by performing clonal tracing and by generating and characterising CAF subtypes starting from human induced pluripotent stem cells; 2) dissect CAF-TME crosstalk by generating 3D patient-derived organoids and spheroids and by analysing their secretome and transcriptomic profiles using high throughput technologies and computational analysis; and 3) reprogramme CAFs by genetic manipulation in favour of therapeutically advantageous subpopulations as a novel therapeutic approach. DynamHet is an ambitious and feasible project that stands as a pioneer in the new concept of deciphering the origin and reprogramming the dynamic heterogeneity of CAFs towards the development of innovative precision medicine approaches in cancer.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores